Skip to main content

Development & Evaluation of a Viable Stent Device for the Treatment of BronchoTracheal Cancer

Objective

Lung cancer is the most common cancer in terms of both incidence and mortality, worldwide. With a median age at diagnosis of 71, lung cancer is mainly affecting the aging population. Airway stenosis is a key problem with significant morbidity and premature death. Endobronchial stenting is a proven therapy to keep the airways open. Nevertheless the currently used clinical stents have major disadvantages either by rapid re-occlusion due to tumour ingrowths (metal stents) or massive mucus retention due to the interrupted mucociliary function (coated stents).
The aim of the project is to develop a viable endobronchial stent (syn. PulmoStent) for the treatment of broncho-tracheal cancer diseases. The concept is based on the combination of stent technologies with the principles of tissue engineering. The PulmoStent is a multi-layered structure providing (1) a functional respiratory epithelium on the luminal side, which allows the maintenance of the mucociliary function in the stented area, (2) an embedded micro- or nanosphere formulations, enabling the sustained, local release of tumour-specific therapeutics in combination with (3) a mechanical separating layer on the external side, enabling a local tumour suppression to avoid stent displacement and restenosis by a growing tumour.
The PulmoStent is a step change beyond the state-of-the-art from a passive to a viable and functional active implant tailored to the patient. It focuses on a clearly identified clinical need for the treatment of lung cancer. The combination of different kinds of biomaterials to a co-scaffold system for the bio-functionalization of the stent will lead to an improved performance of endobronchial stents and thereby to longer durability. The novel PulmoStent will improve the quality of life and increase the life expectancy of lung cancer patients, because of the reduced mucus retention in the stented area, and herewith the reduced risk of life-threatening pneumonia and the local tumour suppression.

Field of science

  • /medical and health sciences/medical biotechnology/tissue engineering
  • /engineering and technology/industrial biotechnology/biomaterials
  • /social sciences/sociology/demography/mortality
  • /medical and health sciences/clinical medicine/oncology/cancer

Call for proposal

FP7-NMP-2011-SMALL-5
See other projects for this call

Funding Scheme

CP-FP - Small or medium-scale focused research project

Coordinator

UNIVERSITAETSKLINIKUM AACHEN
Address
Pauwelsstrasse 30
52074 Aachen
Germany
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 710 902,92
Administrative Contact
Volker Legewie

Participants (7)

NATIONAL UNIVERSITY OF IRELAND GALWAY
Ireland
EU contribution
€ 557 980
Address
University Road
H91 Galway
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Mari Vahey (Ms.)
RHEINISCH-WESTFAELISCHE TECHNISCHE HOCHSCHULE AACHEN
Germany
EU contribution
€ 383 074
Address
Templergraben 55
52062 Aachen
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Ernst Schmachtenberg (Prof.)
UNIVERSITEIT UTRECHT
Netherlands
EU contribution
€ 406 863
Address
Heidelberglaan 8
3584 CS Utrecht
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Martin De Geest (Mr.)
EPITHELIX SARL
Switzerland
EU contribution
€ 419 610
Address
Chemin Des Aulx 14
1228 Plan Les Ouates
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Ludovic Wiszniewski (Dr.)
ITA TECHNOLOGIETRANSFER GMBH
Germany
EU contribution
€ 184 016
Address
Otto-blumenthal-strasse 1
52074 Aachen
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Eric Wiemer (Mr.)
VYSERA BIOMEDICAL LIMITED
Ireland
EU contribution
€ 367 847
Address
Bmr House Parkmore Industrial Estate
Galway
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Niall Behan (Dr.)
NONWOTECC MEDICAL GMBH

Participation ended

Germany
EU contribution
€ 137 406,08
Address
Nattermannallee 1 Gebaude S 19
50829 Koln
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Jessica Minchau